title: Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus.
abstract: Newcastle disease virus (NDV), an avian pathogen, selectively replicates in and kills neuroblastoma (NB) cells, but not normal fibroblasts in vitro and in vivo in nude mice. NDV cytotoxicity towards NB cells is enhanced by N-myc oncogene amplification. To further define the antineoplastic effects of NDV, we examined NDV's interaction with NB cells following short-term exposure to the differentiating agent, all-trans retinoic acid (RA), and to neuraminidase. The human NB cell line IMR-32, after treatment with 50 mumol/L RA, became eight times more sensitive to NDV in a cytotoxicity assay. A time course study to determine the optimal incubation period of IMR-32 cells with RA indicated that a fourfold increase in sensitivity towards NDV killing occurred after only 8 hours of RA incubation prior to addition of virus. Maximal sensitivity was achieved at 24 hours of RA incubation and remained constant for longer incubation periods (up to 72 hours). The sensitization of IMR-32 NB cells to NDV was constant for RA doses between 3 mumol/L and 50 mumol/L. Plaque formation, which indicates replication, virus spread and cytotoxicity by a single infectious virus particle, was also enhanced by RA. This effect does not appear to require N-myc amplification in the target NB cells since RA had similar effects upon the high N-myc (IMR-32) and the low N-myc expressing cells (SK-N-SH). Enhanced sialylation has been shown by others to mediate the growth inhibitory effects of RA on a variety of tumor lines. Removal of sialic acid from the IMR-32 NB cell surface using Clostridium neuraminidase (2.7 mg/mL) inhibited 75% of NDV plaque formation. These results demonstrate that NDV killing of two NB cell lines is enhanced using clinically achievable levels of RA and that sialylation of the NB cell surface is important for virus binding and cytotoxicity.
authors.affiliation: Department of Surgery, Cook County Hospital, Chicago, IL.
authors.forename: K W
authors.initials: KW
authors.lastname: Reichard
authors.forename: R M
authors.initials: RM
authors.lastname: Lorence
authors.forename: B B
authors.initials: BB
authors.lastname: Katubig
authors.forename: M E
authors.initials: ME
authors.lastname: Peeples
authors.forename: H M
authors.initials: HM
authors.lastname: Reyes
mesh_terms: D003588:Cytopathogenic Effect, Viral; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016259:Genes, myc / Q000187:drug effects; D006801:Humans; D009439:Neuraminidase / Q000494:pharmacology; D009447:Neuroblastoma / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D009522:Newcastle disease virus / Q000254:growth & development / Q000472:pathogenicity*; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000382:microbiology; D010948:Viral Plaque Assay
chemical_list: D014212:Tretinoin; D009439:Neuraminidase